Stem cell therapy in pulmonary hypertension: current practice and future opportunities
Pulmonary hypertension (PH) is a progressive disease characterised by elevated pulmonary arterial pressure and right-sided heart failure. While conventional drug therapies, including prostacyclin analogues, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors, have been shown to i...
Main Authors: | Ruixuan Zheng, Tingting Xu, Xinghong Wang, Lehe Yang, Jian Wang, Xiaoying Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2023-09-01
|
Series: | European Respiratory Review |
Online Access: | http://err.ersjournals.com/content/32/169/230112.full |
Similar Items
-
Natural Products for the Treatment of Pulmonary Hypertension: Mechanism, Progress, and Future Opportunities
by: Zuomei Zeng, et al.
Published: (2023-03-01) -
NEW OPPORTUNITIES PATHOGENETIC THERAPY OF PULMONARY ARTERIAL HYPERTENSION
by: T. V. Martynuk, et al.
Published: (2013-03-01) -
CDK4/6 inhibitors in lung cancer: current practice and future directions
by: Shuoshuo Lv, et al.
Published: (2024-02-01) -
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
by: Xuelian Liu, et al.
Published: (2023-01-01) -
Current developments and opportunities of pluripotent stem cells-based therapies for salivary gland hypofunction
by: Wenpeng Song, et al.
Published: (2024-01-01)